HOLX - Hologic, Inc Stock Analysis
Hologic, Inc (HOLX) is a publicly traded company listed on the NASD. It operates in the Medical Instruments & Supplies industry, part of the broader Healthcare sector. The company has a market capitalization of 16.50B, generates annual revenue of 4.10B, and reports net income of 565.80M. As of the latest data, the stock is trading at 74.15 USD.
From a valuation and risk perspective, the stock presents the following profile: The stock is moderately valued and aligns with market expectations for established companies. The PEG ratio is above 2, which could imply the stock is overvalued based on its growth outlook. The company maintains a healthy balance between debt and equity, which is typical for stable businesses. This stock does not currently pay a dividend. This stock tends to be less volatile than the overall market, often preferred by conservative investors.
Analyst recommendation stands at Hold (3.52), indicating current market sentiment. Institutional ownership is reported at 99.65%, reflecting confidence from large investors. Over the last 12 months, the stock has shown a performance of -7.03%, trading within a 52-week range of 51.90 - 80.31.
HOLX - Hologic, Inc
74.15
Analyst Consensus
Hold 3.52
HOLX – Analyst Rating Summary
- Strong Buy: 4
- Buy: 5
- Hold: 16
- Sell: 0
- Strong Sell: 0
- Total Analysts: 25
| Index: | S&P 500 | P/E: | 29.86 | EPS (ttm): | 2.48 | Insider Own: | 1.02% | Shs Outstand: | 222.57M | Perf Week: | 0.07% |
| Market Cap: | 16.50B | Forward P/E: | 14.81 | EPS next Y: | 5.01 | Insider Trans: | -6.03% | Shs Float: | 220.30M | Perf Month: | 8.25% |
| Income(ttm): | 565.80M | PEG: | 3.54 | EPS next Q: | 1.09 | Inst Own: | 99.65% | Short Float: | 1.54% | Perf Quarter: | 10.23% |
| Revenue(ttm): | 4.10B | P/S: | 4.02 | EPS this Y: | 6.51% | Inst Trans: | 5.70% | Short Ratio: | 1.17 | Perf Half Y: | 30.57% |
| Book/sh: | 21.79 | P/B: | 3.40 | EPS next Y: | 10.33% | ROA: | 6.23% | Short Interest: | 3.39M | Perf Year: | -7.03% |
| Cash/sh: | 9.90 | P/C: | 7.49 | EPS next 5Y: | 8.43% | ROE: | 11.12% | 52W Range: | 51.90 - 80.31 | Perf YTD: | 2.86% |
| Dividend Est.: | - | P/FCF: | 17.94 | EPS past 3/5Y: | -21.41% -9.99% | ROIC: | 7.49% | 52W High: | 80.31 -7.67% | Beta: | 0.70 |
| Dividend TTM: | - | Quick Ratio: | 3.06 | Sales past 3/5Y: | -5.53% 1.66% | Gross Margin: | 55.78% | 52W Low: | 51.90 42.87% | Perf 5Y: | 8.49% |
| Dividend Ex-Date: | - | Current Ratio: | 3.75 | EPS Y/Y TTM: | -25.29% | Oper. Margin: | 23.63% | RSI (14): | 66.44 | Volatility: | 0.40% 0.55% |
| Employees: | 7063 | Debt/Eq: | 0.50 | Sales Y/Y TTM: | 1.74% | Profit Margin: | 13.80% | Recom: | 2.68 | Target Price: | 76.80 |
| Option/Short: | Yes / Yes | LT Debt/Eq: | 0.50 | EPS Q/Q: | 9.66% | Payout: | 0.00% | Rel Volume: | 1.83 | Prev Close: | 74.26 |
| Sales Surprise: | 1.48% | EPS Surprise: | 2.89% | Sales Q/Q: | 6.24% | Earnings: | Nov 03 AMC | Avg Volume: | 2.89M | Price: | 74.15 |
| SMA20: | 0.21% | SMA50: | 6.29% | SMA200: | 14.57% | Overbought: -3.57% | Volume: | 5,295,238 | Change: | -0.15% | |
Graham Classic formula value: 56.48
(P/E=8 * 1g) Min value: 36.59
(current P/E * 2g) Max value: 104.04
Average value: 65.7
About Hologic, Inc
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women's health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.
Attention! Trading on the stock market involves financial risks and is not suitable for everyone. The www.stocks-expert.com does not provide financial market trading services; it is for informational purposes only and is not responsible for the consequences of your trading decisions or the operation of the software. Before starting to trade in any markets, make sure you understand the risks associated with trading and that you have a sufficient level of training.